Denali Therapeutics (DNLI) Competitors $15.35 +0.35 (+2.33%) Closing price 04:00 PM EasternExtended Trading$15.38 +0.03 (+0.20%) As of 07:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock DNLI vs. BEAM, BBIO, VRNA, ROIV, ELAN, RVMD, LEGN, GRFS, TGTX, and NUVLShould you be buying Denali Therapeutics stock or one of its competitors? The main competitors of Denali Therapeutics include Beam Therapeutics (BEAM), BridgeBio Pharma (BBIO), Verona Pharma PLC American Depositary Share (VRNA), Roivant Sciences (ROIV), Elanco Animal Health (ELAN), Revolution Medicines (RVMD), Legend Biotech (LEGN), Grifols (GRFS), TG Therapeutics (TGTX), and Nuvalent (NUVL). These companies are all part of the "pharmaceutical products" industry. Denali Therapeutics vs. Its Competitors Beam Therapeutics BridgeBio Pharma Verona Pharma PLC American Depositary Share Roivant Sciences Elanco Animal Health Revolution Medicines Legend Biotech Grifols TG Therapeutics Nuvalent Denali Therapeutics (NASDAQ:DNLI) and Beam Therapeutics (NASDAQ:BEAM) are both mid-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their dividends, risk, earnings, profitability, valuation, analyst recommendations, institutional ownership and media sentiment. Does the media prefer DNLI or BEAM? In the previous week, Denali Therapeutics had 1 more articles in the media than Beam Therapeutics. MarketBeat recorded 8 mentions for Denali Therapeutics and 7 mentions for Beam Therapeutics. Denali Therapeutics' average media sentiment score of 0.85 beat Beam Therapeutics' score of 0.60 indicating that Denali Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Denali Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Beam Therapeutics 3 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has better valuation & earnings, DNLI or BEAM? Beam Therapeutics has lower revenue, but higher earnings than Denali Therapeutics. Denali Therapeutics is trading at a lower price-to-earnings ratio than Beam Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioDenali Therapeutics$330.53M6.75-$422.77M-$2.67-5.75Beam Therapeutics$63.52M34.88-$376.74M-$4.61-4.78 Do analysts prefer DNLI or BEAM? Denali Therapeutics presently has a consensus target price of $33.71, indicating a potential upside of 119.64%. Beam Therapeutics has a consensus target price of $48.75, indicating a potential upside of 121.29%. Given Beam Therapeutics' higher possible upside, analysts plainly believe Beam Therapeutics is more favorable than Denali Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Denali Therapeutics 0 Sell rating(s) 1 Hold rating(s) 14 Buy rating(s) 2 Strong Buy rating(s) 3.06Beam Therapeutics 0 Sell rating(s) 2 Hold rating(s) 11 Buy rating(s) 2 Strong Buy rating(s) 3.00 Which has more risk and volatility, DNLI or BEAM? Denali Therapeutics has a beta of 1.33, indicating that its share price is 33% more volatile than the S&P 500. Comparatively, Beam Therapeutics has a beta of 2.07, indicating that its share price is 107% more volatile than the S&P 500. Is DNLI or BEAM more profitable? Denali Therapeutics has a net margin of 0.00% compared to Beam Therapeutics' net margin of -609.24%. Denali Therapeutics' return on equity of -35.90% beat Beam Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Denali TherapeuticsN/A -35.90% -32.41% Beam Therapeutics -609.24%-44.24%-30.97% Do institutionals and insiders believe in DNLI or BEAM? 92.9% of Denali Therapeutics shares are owned by institutional investors. Comparatively, 99.7% of Beam Therapeutics shares are owned by institutional investors. 12.5% of Denali Therapeutics shares are owned by insiders. Comparatively, 3.5% of Beam Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. SummaryDenali Therapeutics beats Beam Therapeutics on 9 of the 16 factors compared between the two stocks. Get Denali Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for DNLI and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding DNLI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart DNLI vs. The Competition Export to ExcelMetricDenali TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.18B$2.96B$5.56B$9.04BDividend YieldN/A2.42%5.25%4.03%P/E Ratio-5.758.0519.5820.23Price / Sales6.75296.11442.27127.79Price / CashN/A42.7337.5058.41Price / Book1.807.748.085.60Net Income-$422.77M-$54.96M$3.16B$248.43M7 Day Performance4.46%6.04%3.77%5.15%1 Month Performance0.59%4.47%3.90%7.62%1 Year Performance-29.10%6.12%34.22%21.56% Denali Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)DNLIDenali Therapeutics4.7159 of 5 stars$15.35+2.3%$33.71+119.6%-28.4%$2.18B$330.53M-5.75430News CoverageAnalyst RevisionBEAMBeam Therapeutics2.6909 of 5 stars$19.18-4.1%$48.75+154.2%-10.0%$1.93B$63.52M-4.16510News CoverageGap UpBBIOBridgeBio Pharma4.6884 of 5 stars$43.50-1.1%$58.85+35.3%+78.9%$8.26B$221.90M-12.32400Analyst UpgradeVRNAVerona Pharma PLC American Depositary Share1.7228 of 5 stars$91.20-0.4%$107.36+17.7%+514.8%$7.76B$42.28M-45.6030Trending NewsAnalyst ForecastROIVRoivant Sciences2.1984 of 5 stars$10.74-2.3%$17.50+62.9%+3.6%$7.30B$29.05M-42.96860News CoverageAnalyst ForecastELANElanco Animal Health2.391 of 5 stars$14.48-1.1%$15.33+5.9%+9.1%$7.19B$4.44B19.579,000RVMDRevolution Medicines4.5616 of 5 stars$36.67-3.2%$67.58+84.3%-12.3%$6.83B$11.58M-9.17250News CoverageLEGNLegend Biotech2.9297 of 5 stars$35.87+0.6%$72.60+102.4%-15.5%$6.59B$728.30M-60.802,609Positive NewsAnalyst ForecastGRFSGrifols3.6388 of 5 stars$8.87-2.3%$10.30+16.1%+12.2%$6.10B$7.81B7.5823,822Analyst UpgradeGap UpTGTXTG Therapeutics4.021 of 5 stars$35.98-2.0%$40.80+13.4%+90.5%$5.71B$329M149.92290Positive NewsAnalyst ForecastNUVLNuvalent3.8058 of 5 stars$77.93-3.2%$119.60+53.5%+10.7%$5.60BN/A-17.7540 Related Companies and Tools Related Companies Beam Therapeutics Competitors BridgeBio Pharma Competitors Verona Pharma PLC American Depositary Share Competitors Roivant Sciences Competitors Elanco Animal Health Competitors Revolution Medicines Competitors Legend Biotech Competitors Grifols Competitors TG Therapeutics Competitors Nuvalent Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:DNLI) was last updated on 7/10/2025 by MarketBeat.com Staff From Our PartnersI was wrong about TrumpI made a mistake. A mistake I feel very foolish about. After speaking with Donald Trump and some of his ...Porter & Company | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | Sponsored"I'm risking my reputation on this"I've stayed quiet for too long, but after everything I've uncovered about what's brewing in the 2025 crypto ma...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Denali Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Denali Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free DNLI Stock Alerts